Catheter Precision, Inc. Reports Q3 Financial Results and Operational Updates

Catheter Precision, Inc., a U.S.-based medical device company focusing on electrophysiology, announced its third-quarter financial results. With total assets of $26.7 million, the company reported sales revenue of approximately $96,000 for the quarter, resulting in a net loss of $4.1 million, largely due to commercial activities. The company's cash position at the end of the quarter was $1.3 million.

The company continues its commercial expansion with 87 hospitals in its customer pipeline, and it performed several successful VIVO procedures across Europe. Additionally, Catheter Precision is aiming to obtain the CE Mark for its LockeT device by Q1 2025, with plans for a subsequent European launch.

In terms of research, Catheter Precision released a study on the LockeT device in the Journal of Cardiovascular Electrophysiology and highlighted the VIVO product in HeartRhythm Case Reports. Ongoing studies are focusing on product efficacy and procedural workflow improvements.